ArticleIntestinal research2017

Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study.

Wei-Chen Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.